Thyroid Eye Disease Market Expands With Targeted Therapies and Improved Diagnosis

Early identification is particularly important because intervention during the active inflammatory phase may improve long-term outcomes. However, mild disease can remain undiagnosed, limiting access to timely treatment. Increasing awareness among clinicians and patients is therefore expected to support diagnosis and contribute to market expansion.

The treatment landscape has evolved considerably. Before the introduction of targeted therapy, corticosteroids, immunosuppressants, orbital radiation, and off-label biologics such as rituximab and tocilizumab were commonly used for moderate-to-severe active disease. DelveInsight notes that these approaches represented a market of approximately USD 37 million across the 7MM before 2019.

Thyroid Eye Disease Market Drivers

One of the strongest growth factors is the increasing recognition of untreated and undertreated TED. The condition can produce persistent ocular symptoms, cosmetic changes, functional impairment, and, in severe cases, sight-threatening complications. As awareness improves, more patients are expected to undergo appropriate evaluation and enter treatment pathways.

The approval of TEPEZZA (teprotumumab) in the United States significantly changed the therapeutic landscape. DelveInsight identifies TEPEZZA as the only FDA-approved therapy specifically indicated for TED in the report. The treatment targets insulin-like growth factor-1 receptor (IGF-1R), a pathway implicated in the disease process. Clinical benefits include reductions in proptosis and diplopia as well as improvements in disease activity and quality of life.

This targeted approach has helped establish biologics as an important component of the evolving us thyroid disorder market, while also encouraging pharmaceutical companies to investigate alternative mechanisms, administration routes, and treatment strategies.

Another major driver is the unmet need among patients who require more convenient, effective, or durable treatment. Only a portion of patients with TED develop acute moderate-to-severe disease requiring drug therapy. DelveInsight estimates that approximately 20% of cases are treated for acute disease, suggesting substantial potential for market expansion as diagnosis improves and safer and more effective therapies become available.

Thyroid Eye Disease Market Barriers

Despite substantial commercial potential, several challenges may restrict market growth. The heterogeneous presentation of TED makes diagnosis difficult, particularly in patients with mild, unilateral, euthyroid, or atypical disease. Delayed diagnosis can prevent patients from receiving treatment during the active inflammatory stage when therapeutic intervention may be most beneficial.

Treatment-related safety concerns and administration requirements can also influence adoption. Conventional corticosteroid therapy is associated with significant adverse effects, while intravenous biologic treatment can require repeated healthcare visits. These limitations create opportunities for alternative delivery methods but can also contribute to treatment discontinuation or reluctance among patients and physicians.